The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY) and MacroGenics (MGNX), due to issues found at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results